Article
 

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

Público Deposited

Contenido Descargable

Descargar PDF
https://ir.library.oregonstate.edu/concern/articles/bk128c69g

Descriptions

Attribute NameValues
Creator
Abstract
  • An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non–high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care.
  • This is the publisher’s final pdf. The article is copyrighted by National Lipid Association and published by Elsevier. It can be found at: http://www.journals.elsevier.com/journal-of-clinical-lipidology/
  • Keywords: Clinical recommendations, Residual risk, Elderly, Team-based care, Dyslipidemia, Human immunodeficiency virus, Lifestyle therapies, Adherence, Children, Rheumatoid arthritis
Resource Type
DOI
Fecha Disponible
Fecha de Emisión
Citation
  • Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., ... & Underberg, J. A. (2015). National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. Journal of Clinical Lipidology, 9(6), S1-S122. doi:10.1016/j.jacl.2015.09.002
Journal Title
Journal Volume
  • 9
Journal Issue/Number
  • 6 Suppl.
Declaración de derechos
Funding Statement (additional comments about funding)
  • T.A.J. discloses that in the past 12 months, he has received consulting fees from Merck and Co, Amarin, Amgen, AstraZeneca, and Regeneron/Sanofi-Aventis. K.C.M. discloses that he has received consulting fees and research grants from AbbVie, Matinas BioPharma, AstraZeneca, Pharmavite, Sancilio & Co., DuPont, ACH Foods, Shaklee, Egg Nutrition Center, National Dairy Council, and National Cattlemen's Beef Association. C.E.O. has nothing to disclose. P.H.J. discloses that he has received consulting or speaker honoraria from Merck and Co., Amgen, and Sanofi-Aventis/Regeneron. P.K.E. has received advisory board honoraria from Solazyme, Avocado Nutrition Sciences Advisors, Seafood Nutrition Partnership, and McDonald's Global Advisory Council. P.K.E. further discloses that she has received research grants from Hershey Foods and Almond Board of CA, Solae/DuPont, California Strawberry Commission, California Walnut Commission, Ag Canada and Canola Oil Council, Ocean Spray Cranberries, and National Cattlemen's Beef Association. G.S. has nothing to disclose. R.L. has nothing to disclose. S.R.D. has nothing to disclose. D.P.W. discloses that he has received speaker honoraria from Osler Institute, Alexion Pharmaceuticals, and Insulet Corp. and further discloses that he participated on the advisory board for Aegerion Pharmaceuticals and Alexion Pharmaceuticals. D.P.W. also discloses that he has received research funding from Merck Sharpe & Dohme and Novo Nordisk Inc. P.B.M. discloses that she has received advisory board honoraria from Amgen, AstraZeneca, and Sanofi/Regeneron. R.A.W. discloses that he has received consulting honoraria from the National Institutes of Health and the Food and Drug Administration. S.M.G. has nothing to disclose. M.D. has nothing to disclose. K.C.F. discloses that he has received consulting honoraria from Amgen, Sanofi, and Lilly, and further discloses that he received contracted research from Boehringer Ingelheim. K.V. discloses that he received consultant/speaker honoraria from Aegerion, AstraZeneca, Amarin, Amgen, Otsuka, Novartis, and Sanofi. K.V. further discloses that he has received advisory board honoraria from ZS Pharma and Amarin, and received a research grant from Otsuka. P.C.D. has received consultant/speaker honoraria from Amgen, Sanofi/Regeneron, Pfizer, and Merck. J.A.A. received a fee from involvement on the scientific advisory board for Janssen, Merck, and Viiv. K.L. has nothing to disclose. J.M.M. has nothing to disclose. J.L.R. received speaker honoraria from AbbVie, AstraZeneca, Amarin, Amgen, and Sanofi/Regeneron. L.T.B. received speaker honoraria from Practice Point and author/NP advisory board honoraria from UpToDate. M.K.I. discloses that in the past 12 months, he received salary for employment with Sanofi-Aventis. H.E.B. discloses that he has received research grants from Arena Pharmaceuticals, Boehringer Ingelheim, Cargill Inc, GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Shionogi, Takeda, Stratum Nutrition, California Raisin Board, Esperion, Essentialis, Forest, Gilead Sciences Inc, Given, Hoffman-LaRoche, Home Access, Novartis, Omthera, Pfizer, Trygg Pharmaceuticals, TWI Bio, Xoma, Ardea Inc, High Point Pharmaceuticals LLC, Micropharma Limited, TransTech Pharma Inc, TIMI, Pozen, Regeneron, and Elcelyx. H.E.B. further discloses that he has received honoraria/research grants from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Catabasis, Daiichi-Sankyo Inc, Eisai, Merck & Co, VIVUS, Zeomedex, and WPU. W.V.B. is the editor of the Journal of Clinical Lipidology and further discloses that he has received consulting fees/honoraria from Akcea, Esperion, Regeneron, Amgen, Genzyme, Pfizer Inc., Merck and Co, GlaxoSmithKline, Medtelligence, and Vindico.
Publisher
Peer Reviewed
Language
Replaces

Relaciones

Parents:

This work has no parents.

Elementos

Miniatura Título Fecha de subida Visibilidad Acciones
file details JacobsonNationalLipidAssociation.pdf 07/26/2017 Público
file details JacobsonNationalLipidAssociationErratum.pdf 07/26/2017 Público